Universität zu Köln

Doerr, Fabian ORCID: 0000-0002-0878-0406, Stange, Sebastian, Michel, Maximilian, Schlachtenberger, Georg, Menghesha, Hruy, Wahlers, Thorsten, Hekmat, Khosro and Heldwein, Matthias B. (2022). Stage I and II Small-Cell Lung Cancer-New Challenge for Surgery. Lung, 200 (4). S. 505 - 513. NEW YORK: SPRINGER. ISSN 1432-1750

Full text not available from this repository.

Abstract

Purpose The recommended treatment for small-cell lung cancer (SCLC) currently is surgery in stage I disease. We wondered about stage II SCLC and present a meta-analysis on mean-survival of patients that underwent surgery for stage I and II compared to controls. Methods A systematic literature search was performed on December 01st 2021 in Medline, Embase and Cochrane Library. We considered studies published on the effect of surgery in SCLC since 2004 and assessed them using ROBINS-I. We preformed I-2-tests, Q-statistics, DerSimonian-Laird tests and Egger-regression. The meta-analysis was conducted according to PRISMA. Results Out of 6826 records, seven studies with a total of 11,241 patients ('surgery group': 3911 patients; 'non-surgery group': 7330; treatment period: 1984-2015) were included. Heterogeneity between the studies was revealed in absence of any publication bias. Patient characteristics did not differ between the groups (p-value > 0.05). The mean-survival in an analysis of patients in stage I was 36.7 +/- 10.8 months for the 'surgery group' and 20.3 +/- 5.7 months for the 'non-surgery group' (p-value = 0.0084). A combined analysis of patients in stage I and II revealed a mean-survival of 32.0 +/- 16.7 months for the 'surgery group' and 19.1 +/- 6.1 months for the 'non-surgery group' (p-value = 0.0391). In a separate analysis of stage II, we were able to demonstrate a significant survival benefit after surgery (21.4 +/- 3.6 versus 16.2 +/- 3.9 months; p-value = 0.0493). Conclusion Our meta-analysis shows a significant survival benefit after surgery not only in the recommended stage I but also in stage II SCLC. Our data suggests that both stages should be considered for surgery of early SCLC.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Doerr, Fabian UNSPECIFIED orcid.org/0000-0002-0878-0406 UNSPECIFIED Stange, Sebastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Michel, Maximilian UNSPECIFIED UNSPECIFIED UNSPECIFIED Schlachtenberger, Georg UNSPECIFIED UNSPECIFIED UNSPECIFIED Menghesha, Hruy UNSPECIFIED UNSPECIFIED UNSPECIFIED Wahlers, Thorsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Hekmat, Khosro UNSPECIFIED UNSPECIFIED UNSPECIFIED Heldwein, Matthias B. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-662743
DOI:	10.1007/s00408-022-00549-8
Journal or Publication Title:	Lung
Volume:	200
Number:	4
Page Range:	S. 505 - 513
Date:	2022
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1432-1750
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SURGICAL RESECTION; SURVIVAL OUTCOMES; AMERICAN-COLLEGE; MANAGEMENT; CARCINOMA; CHEMOTHERAPY; RADIOTHERAPY; DIAGNOSIS; PROGNOSIS; LOBECTOMY Multiple languages Respiratory System Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66274